Immunotherapy

Immunotherapy is the practice of treating disease by manipulating the immune system itself—harnessing, redirecting, or restraining the body's own defenses rather than attacking a pathogen or tumor directly.

9 frameworks, from 1796 to today · Immunology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Immunotherapy is the practice of treating disease by manipulating the immune system itself—harnessing, redirecting, or restraining the body's own defenses rather than attacking a pathogen or tumor directly1. Its central idea is that the immune system is not merely a passive shield but a tool that can be deliberately tuned: switched on where it is failing, switched off where it is overreacting, or taught to recognize a target it has missed. What is at stake is enormous, because the immune system is implicated in nearly every disease—infections, cancers, allergies, autoimmune conditions, and the rejection of transplanted organs—and because the same system that can cure can also kill. The history of immunotherapy is the story of practitioners learning, often painfully, how to steer a system whose rules they only gradually came to understand.

Variolation and the Birth of Deliberate Immune Manipulation

The oldest form of immunotherapy is vaccination, and its roots reach back before anyone knew what an immune system was. In China and India, practitioners variolated against smallpox by introducing material from a mild case—scabs or pustule fluid—into a healthy person, hoping to induce a survivable infection that would confer lifelong protection. The practice spread to the Ottoman Empire and was observed there by Lady Mary Wortley Montagu, who brought it to Britain in the 1720s23. It worked often enough to be adopted, but it carried real risk: variolated patients could die or seed outbreaks.

The decisive turn came with Edward Jenner, a Gloucestershire physician who in 1796 inoculated a boy with cowpox matter and then exposed him to smallpox, finding him protected425. Jenner published his findings in 179842. The insight was that a related but harmless animal virus could confer immunity to the deadly human one—the principle of using a "vaccine" (from vacca, cow) to train the body without risking the disease425. Vaccination spread worldwide through the nineteenth century, and with Louis Pasteur's work on attenuated pathogens in the 1870s and 1880s—chicken cholera, anthrax, rabies—it became a general method: weaken a microbe, introduce it, and the body learns to resist the real thing. What practitioners could not yet explain was how it worked. That explanation would have to wait for the science of immunology.

Serum Therapy and the Humoral Turn

By the 1880s the germ theory had given medicine its targets, and the question became how the body fights them. Emil von Behring and Shibasaburo Kitasato showed in 1890 that the blood of animals immunized against diphtheria or tetanus contained a substance—an "antitoxin"—that could neutralize the toxin and, crucially, could be transferred to another animal to protect it678910. This was serum therapy: take blood serum from an immunized animal, give it to a sick patient, and the patient gains passive protection6. Behring won the first Nobel Prize in Physiology or Medicine in 1901 for diphtheria antitoxin, which saved many children's lives.

Serum therapy established that immunity could reside in the blood fluid—the "humoral" theory—and it created a practical industry of horses and other animals kept for antiserum production6. But it also revealed limits: sera were foreign proteins, and patients often reacted against them with "serum sickness," a fever-and-rash illness that was itself an immune reaction7. And a rival view, championed by Elie Metchnikoff, held that immunity was chiefly cellular—that phagocytes, cells that engulf microbes, were the real defenders1112. The humoral-versus-cellular debate would run for decades. Serum therapy also pointed toward a future idea: if antibodies could be given, perhaps they could be made specific and pure.

Allergen Immunotherapy and the Idea of Tolerance

A different strand emerged from the clinic. In the early twentieth century, physicians treating hay fever noticed that some patients improved after repeated exposure to the offending pollen1. In 1911 Leonard Noon and John Freeman in London reported that injecting increasing doses of grass pollen extract could desensitize patients—reduce their symptoms13. This was allergen immunotherapy, and its logic was the opposite of vaccination's: instead of provoking immunity to a microbe, it aimed to quiet an immune response that had gone wrong113. The mechanism was obscure, but the practice endured, and it introduced a durable principle—that the immune system can be taught tolerance, not only attack. The same principle would later underlie attempts to prevent transplant rejection and to treat autoimmune disease.

Transplantation and the Problem of Suppression

The mid-twentieth century brought a new problem: if the immune system attacks foreign tissue, how can a surgeon replace a failing organ? Early transplant attempts failed because the recipient's immune system destroyed the graft. The breakthrough came from understanding why: Peter Medawar and colleagues in Britain, studying skin grafts in rabbits and mice during the 1940s, showed that rejection was an active immune response, and that animals exposed to foreign tissue in early life could later accept it—a state called tolerance. Medawar shared the 1960 Nobel Prize with Macfarlane Burnet for this work14.

Clinically, the answer was to suppress the immune system. Total-body irradiation was tried, then drugs. The decisive drug was azathioprine, developed in the late 1950s and combined with steroids by Joseph Murray's team in Boston; in 1954 Murray had performed the first successful kidney transplant between identical twins (no rejection problem), and in the early 1960s immunosuppressed transplants between unrelated people began to succeed. Cyclosporine, introduced in the late 1970s, was a further leap: it suppressed rejection more selectively by blocking T-cell activation. Transplantation immunosuppression taught medicine that the immune system could be pharmacologically restrained—a lesson that cut both ways, since suppressed patients fell prey to infections and cancers. The dream of inducing specific tolerance, rather than blanket suppression, remained open.

The Antibody Revolution

The humoral tradition returned in a new form. In 1975 Georges Köhler and César Milstein developed hybridoma technology: they fused an antibody-producing B cell with an immortal myeloma cell, creating a hybrid cell line that could produce a single, uniform antibody indefinitely. These monoclonal antibodies—identical molecules aimed at one target—transformed both research and therapy. Early therapeutic monoclonals were mouse proteins and provoked human immune responses, but "humanization" and later fully human antibodies reduced this. By the 1990s and 2000s, monoclonal antibodies entered the clinic for cancer (rituximab against lymphoma, trastuzumab against HER2-positive breast cancer), autoimmune disease, and transplant rejection. The antibody, once a mysterious serum component, had become a designer drug.

Adoptive Cell Therapy and the Cancer Vaccination Dream

A parallel tradition sought to use cells themselves as therapy. Adoptive cell therapy means taking immune cells out of the body, expanding or engineering them, and returning them to fight disease. Early work in the 1980s by Steven Rosenberg and others used tumor-infiltrating lymphocytes—immune cells found inside tumors—expanded in the laboratory and reinfused into patients, with occasional dramatic responses in melanoma115. The approach was laborious and worked only in some cancers, but it proved that a patient's own cells could be turned into a treatment.

Alongside it ran therapeutic cancer vaccination: the hope that a vaccine could teach the immune system to attack a tumor, much as it attacks a microbe. Despite decades of effort and many trials, cancer vaccines largely disappointed, because tumors are poor immunogens and actively suppress immune responses. The failures were instructive: they showed that the obstacle was not merely recognition but the tumor's ability to shut down the attack.

Checkpoint Blockade: Releasing the Brakes

That obstacle was named and then dismantled. The immune system has built-in brakes—"checkpoints"—that prevent it from attacking normal tissue. Tumors exploit these brakes. In the 1990s James Allison showed that blocking CTLA-4, a brake on T cells, could unleash anti-tumor immunity in mice; in 1996 his group reported that anti-CTLA-4 antibodies caused tumor rejection. Independently, Tasuku Honjo's work on PD-1, another inhibitory receptor, laid the groundwork for a second brake. The first checkpoint-blockade drug, ipilimumab (anti-CTLA-4), was approved in 2011 for melanoma, and PD-1 blockers followed. Allison and Honjo shared the 2018 Nobel Prize1151617. Checkpoint blockade was a conceptual revolution: instead of adding an attack, it removed a restraint, and in some patients—a minority, but sometimes for years—it produced durable remissions in cancers that had been uniformly fatal. It also produced a new class of side effects, autoimmune-like toxicities, because releasing the brakes can turn the immune system on the body itself.

CAR T Cells: Engineering the Attack

The most recent major turn combines cell therapy with genetic engineering. Chimeric antigen receptor (CAR) T-cell therapy takes a patient's T cells, engineers them to carry a synthetic receptor that recognizes a specific marker on tumor cells, and reinfuses them115. The receptor—a "chimeric antigen receptor"—joins an antibody-like recognition domain to T-cell signaling machinery, so the engineered cell both finds and kills its target. Early clinical success came in the 2010s against B-cell leukemias and lymphomas, where the target (CD19) is present on malignant and normal B cells alike; the treatment can be curative but also destroys normal B cells and can trigger severe "cytokine release syndrome," a dangerous inflammatory storm. CAR T-cell therapy was approved in 2017 for certain leukemias and lymphomas, and it opened the question of how to extend the approach to solid tumors, which lack such clean targets.

The Present: A Toolkit of Approaches

Immunotherapy today is not one method but a family of them, each descending from a distinct strand of this history. Vaccination remains the most widely used immunotherapy in the world, now with mRNA platforms that can be redesigned rapidly. Allergen immunotherapy persists as desensitization for allergy113. Transplantation relies on refined immunosuppressive drugs and increasingly on antibody-based induction. Monoclonal antibodies are a mainstay of cancer and autoimmune therapy. Checkpoint blockade and CAR T cells are the newest and most dramatic, and they have made cancer immunotherapy a central clinical field. Adoptive cell therapy continues to expand beyond CAR T cells, and therapeutic cancer vaccination has been revived by better understanding of tumor immunology.

The open questions are the ones the history keeps posing. How can the immune system be turned on against cancer without turning on the body? How can tolerance be induced specifically, so that transplants survive and autoimmune disease is quieted without blanket suppression? Why do checkpoint blockade and CAR T cells work spectacularly in some patients and not at all in others? And how can the power of the immune system be extended to the solid tumors that still resist it? The field's history is a record of learning to steer a system that was never designed to be steered—and of discovering, again and again, that its brakes and accelerators are more intricate than they first appeared.

References

  1. Immunotherapy (introduction, Allergen immunotherapy, Adoptive cell therapy, Cancer), Wikipedia
  2. Vaccine (introduction, History), Wikipedia
  3. Immunization (History), Wikipedia
  4. Vaccination (introduction, History), Wikipedia
  5. Smallpox vaccine, Wikipedia
  6. Antiserum (History, introduction), Wikipedia
  7. Antitoxin (History of antitoxin, introduction), Wikipedia
  8. Antibody (History), Wikipedia
  9. Passive immunity (History and applications of artificial passive immunity), Wikipedia
  10. Antivenom (History), Wikipedia
  11. Immunology, Wikipedia
  12. Immune system (History of immunology), Wikipedia
  13. Allergen immunotherapy (introduction, History), Wikipedia
  14. Immune tolerance (Historical background), Wikipedia
  15. Cancer immunotherapy (History, introduction), Wikipedia
  16. Checkpoint inhibitor, Wikipedia
  17. Immune checkpoint, Wikipedia

The frameworks of Immunotherapy

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1796-Present

    Vaccination

    How can exposure to a mild form of a disease prevent the severe form?

    Fly to its tower in Nousfarer

  2. 1890-1940

    Antiserum

    Can protective substances from immune blood be transferred to cure disease?

    Fly to its tower in Nousfarer

  3. 1911-Present

    Allergen immunotherapy

    Can repeated exposure to an allergen reduce allergic symptoms?

    Fly to its tower in Nousfarer

  4. 1954-Present

    Transplant immunosuppression

    How can a transplanted organ be kept from being rejected?

    Fly to its tower in Nousfarer

  5. 1975-Present

    Monoclonal antibody therapy

    Can a single pure antibody be made to target one molecule?

    Fly to its tower in Nousfarer

  6. 1980-Present

    Adoptive cell transfer

    Can a patient's own immune cells be used as a treatment?

    Fly to its tower in Nousfarer

  7. 1980-Present

    Therapeutic cancer vaccination

    Can a vaccine teach the immune system to attack a tumor?

    Fly to its tower in Nousfarer

  8. 1996-Present

    Checkpoint inhibitor

    Can removing the immune system's brakes unleash an attack on cancer?

    Fly to its tower in Nousfarer

  9. 2011-Present

    CAR T-cell therapy

    Can engineered immune cells be made to hunt and kill cancer?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

VaccinationAntiserumAllergen immunotherapyTransplant immunosuppressionMonoclonal antibody therapyAdoptive cell transferTherapeutic cancer vaccinationCheckpoint inhibitorCAR T-cell therapy

Beyond the field

Where Immunotherapy's ideas came from in other fields, and what they led to there: the strongest 12 of 60 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Immunotherapy is a planet in Nousfarer

Its city has a tower for each of these 9 frameworks. Land, walk in, and climb one concept at a time.

Land on Immunotherapy

Related fields

Fields its ideas are linked to

More in Immunology

See where Immunotherapy sits on the Map of Human Knowledge